ProMIS Neurosciences Inc. (PMN)
| Bid | 0.62 |
| Market Cap | 21.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 0.11 |
| PE Ratio (ttm) | 5.94 |
| Forward PE | -1.49 |
| Analyst | Buy |
| Ask | 0.79 |
| Volume | 34,375 |
| Avg. Volume (20D) | 42,558 |
| Open | 0.74 |
| Previous Close | 0.71 |
| Day's Range | 0.64 - 0.74 |
| 52-Week Range | 0.62 - 2.61 |
| Beta | 0.58 |
About PMN
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded protei...
Analyst Forecast
According to 1 analyst ratings, the average rating for PMN stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 818.84% from the latest price.
Stock Forecasts
1 year ago · proactiveinvestors.com
ProMIS Neurosciences submits IND application for Alzheimer's treatmentProMIS Neurosciences (TSX:PMN) told investors it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for PMN310 for the treatment of Alzheimer's di...